Opioid antagonist naltrexone for the treatment of pathological gambling in parkinson disease

Clinical Neuropharmacology

Volumn 35, Issue 3, 2012, Pages 118-120

  Bosco, Domenico ^a   Plastino, Massimiliano ^a   Colica, Carmela ^b   Bosco, Francesca ^c   Arianna, Spanò ^c   Vecchio, Antonino ^d   Galati, Francesco ^d   Cristiano, Dario ^a   Consoli, Arturo ^e   Consoli, Domenico ^d  

^a Department of Neurology S Giovanni di Dio ^*  (Italy)

^b Neurological Science Institute   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d G Jazzolino Hospital   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

dopamine replacement therapy; naltrexone; opioid antagonist; Parkinson disease; pathological gambling

Indexed keywords

ALPRAZOLAM; BIPERIDEN; LAMOTRIGINE; LEVODOPA; NALTREXONE; PAROXETINE; PRAMIPEXOLE; ROPINIROLE; SERTRALINE; VENLAFAXINE;

ADULT; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; BRAIN DEPTH STIMULATION; CASE REPORT; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; IMPULSE CONTROL DISORDER; LIVER DISEASE; LIVER EXAMINATION; MAJOR DEPRESSION; MALE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SIDE EFFECT;

ADULT; DOPAMINE AGONISTS; GAMBLING; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PARKINSON DISEASE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84861527632     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31824d529b     Document Type: Article

References (24)

1. American Psychiatric Association. DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington. DC: American Psychiatric Association; 1994:609Y621.
2. Bergh C, Eklund T, Södersten P, et al. Altered dopamine function in pathological gambling. Psychol Med 1997;27:473Y475.
3. Molina JA, Sàinz-Artiga MJ, Fraile A, et al. Pathological gambling in Parkinson's disease: a behavioural manifestation of pharmacological treatment? Mov Disord 2000;15:869Y872.
4. Zald D, Boileau I, EI-Dearedy W, et al. Dopamine neurotransmission in the human striatum during monetary reward tasks. J Neuroscience 2004;24:4105Y4112.
5. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson's disease. Arch Neurol 2005;62:1377Y1381.
6. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 2004;19:433Y437.
7. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61:422Y423.
8. Ardouin C, Voon V,Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006;21:1941Y1946.
9. Rotondo A, Bosco D, Plastino M, et al. Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord 2010;25(12):1994Y1995.
10. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001;49:914Y921.
11. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist Nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006;163:303Y312.
12. Fahn S, Elton RL, and members of the UPDRS Developtment Committee. Unified Parkinson's Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Development in Parkinson's Disease. Florham Park, NJ: MacMillan; 1987;11:153Y163.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427Y442.
14. Voon V, Fox SH. Medication-related impulse control and repetitive behaviours in Parkinson disease. Arch Neurol 2007;64:1089Y1096.
15. Sevincok L, Akoglu A, Akyol A. Quietapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol 2007;27:107Y108.
16. Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson disease. Mov Disord 2008;23:75Y80.
17. Black KJ, Friedman JH. Repetitive and impulsive behaviors in treated Parkinson disease. Neurology 2006;67:1118Y1119.
18. Anton RF, Moak DH, Waid LR, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999;156:1758Y1764.
19. Kosten TR, Kleber HD, Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 1989;44:887Y892.
20. Darland T, Heinricher MM, Grandy DK. Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci 1998;21:215Y221.
21. Marti M, Mela F, Veronesi C, et al. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci 2004;24:6659Y6666.
22. Marti M, Guerrini R, Beani L, et al. Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat. Neuroscience 2002;112:153Y160.
23. Marti M, Mela F, Fantin M, et al. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci 2005;25:9591Y9601.
24. Dannon PN, Lowengrub K, Musin E, et al. 12-months follow-up study of drug treatment in pathological gamblers: a primary outcome study. J Clin Psychopharmacol 2007;27(6):620Y624.